NPM1 and acute myeloid leukemia: More recently, it has been shown that IKAROS degradation via mezigdomide has demonstrated pre-clinical activity in KMT2A-r and NPM1-mutated AML cells, and may also have efficacy in combination with menin inhibition [136].